Immunosuppression without calcineurin inhibition: Optimization of renal function in expanded criteria donor renal transplantation

Clinical Transplantation

Volumn 23, Issue 1, 2009, Pages 9-15

  Luke, Patrick P W ^a   Nguan, Christopher Y ^b   Horovitz, David ^a   Gregor, Laura ^a   Warren, Jeff ^a   House, Andrew A ^a  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Calcineurin inhibitor; Expanded donor; Renal transplantation

Indexed keywords

BASILIXIMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ESOPHAGITIS; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART INFARCTION; HEMODIALYSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY DONOR; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LUNG EMBOLISM; LYMPHOCELE; MALE; MOUTH ULCER; PRIORITY JOURNAL; TREATMENT OUTCOME; WOUND COMPLICATION;

CALCINEURIN; CASE-CONTROL STUDIES; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PILOT PROJECTS; PREDNISONE; PROSPECTIVE STUDIES; SIROLIMUS; SURVIVAL RATE; TREATMENT OUTCOME; WAITING LISTS;

EID: 63349112513     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2008.00880.x     Document Type: Article

References (26)

1. Min DI, Monaco AP. Complications associated with immunosuppressive therapy and their management. Pharmacotherapy 1991: 11: 119S.
2. Halloran P, Mathew T, Tomlanovich S et al. Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997: 63: 39.
3. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study. The Rapamune US Study Group. Lancet 2000: 356: 194.
4. Flechner SM, Goldfarb D, Modlin C et al. Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002: 74: 1070.
5. Larson TS, Dean PG, Stegall MD et al. Complete avoidance of calcineurin inhibitors in renal transplantation: A randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006: 6: 514.
6. Flechner SM, Kurian SM, Solez K et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004: 4: 1776.
7. Flechner SM, Goldfarb D, Solez K et al. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation 2007: 83: 883.
8. Scientific Registry of Transplant Recipients: OPTN/SRTR 2005 Annual Report. 2007 (January/20).
9. Ojo AO, Hanson JA, Meier-Kriesche H et al. Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. J Am Soc Nephrol 2001: 12: 589.
10. Whiting JF, Golconda M, Smith R et al. Economic costs of expanded criteria donors in renal transplantation. Transplantation 1998: 65: 204.
11. United Network for Organ Sharing: UNOS Policy 3.5.1. Definition of Expanded Criteria Donor and Standard Donor, 2006, 2007.
12. Brennan DC, Daller JA, Lake KD et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006: 355: 1967.
13. Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and meta-analysis of randomized trials. Transplantation 2006: 81: 1234.
14. Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients. Cochrane Database Syst Rev 2006: 2: CD004290.
15. Groth CG, Backman L, Morales JM et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999: 67: 1036.
16. Srinivas TR, Schold JD, Guerra G et al. Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation. Am J Transplant 2007: 7: 586.
17. Swanson SJ, Hale DA, Mannon RB et al. Kidney transplantation with rabbit antithymocyte globulin nduction and sirolimus monotherapy. Lancet 2002: 360: 1662.
18. Shaffer D, Langone A, Nylander WA et al. A pilot protocol of a calcineurin-inhibitor free regimen for kidney transplant recipients of marginal donor kidneys or with delayed graft function. Clin Transplant 2003: 17: 31.
19. Furian L, Baldan N, Margani G et al. Calcineurin inhibitor-free immunosuppression in dual kidney transplantation from elderly donors. Clin Transplant 2007: 21: 57.
20. Re LS, Rial MC, Guardia OE et al. Results of a calcineurin-inhibitor-free immunosuppressive protocol in renal transplant recipients of expanded criteria deceased donors. Transplant Proc 2006: 38: 3468.
21. Pisani F, Buonomo O, Iaria G et al. Sirolimus in kidney transplantation from marginal donors. Transplant Proc 2004: 36: 495.
22. Cruzado JM, Bestard O, Riera L et al. Immunosuppression for dual kidney transplantation with marginal organs: The old is better yet. Am J Transplant 2007: 7: 639.
23. Nankivell BJ, Borrows RJ, Fung CL et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003: 349: 2326.
24. Nankivell BJ, Borrows RJ, Fung CL et al. Calcineurin inhibitor nephrotoxicity: Longitudinal assessment by protocol histology. Transplantation 2004: 78: 557.
25. N ickel T, S chlichting CL, W eis M. Drugs modulating endothelial function after transplantation. Transplantation 2006: 82: S41.
26. Ponticelli C. The pleiotropic effects of mTor inhibitors. J Nephrol 2004: 17: 762.